Filing Details
- Accession Number:
- 0001140361-22-046568
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-21 21:32:30
- Reporting Period:
- 2022-12-19
- Accepted Time:
- 2022-12-21 21:32:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1746473 | Pliant Therapeutics Inc. | PLRX | Pharmaceutical Preparations (2834) | 474272481 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1822619 | Mike Ouimette | C/O Pliant Therapeutics, Inc. 260 Littlefield Avenue South San Francisco CA 94080 | General Counsel & Corp. Sec'y | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-12-19 | 13,594 | $0.00 | 13,594 | No | 4 | A | Direct | |
Common Stock | Disposition | 2022-12-20 | 4,719 | $19.10 | 8,875 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- On July 28, 2022, the Reporting Person was granted 54,375 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 13,594 shares.
- The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (2) to this Form 4.